Related Experiment Video
Updated: Dec 29, 2025

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan
Published on: June 29, 2018
Reference Datasets for Studies in a Replicate Design Intended for Average Bioequivalence with Expanding Limits
Helmut Schütz1, Detlew Labes2, Michael Tomashevskiy3
1BEBAC, Neubaugasse 36/11, 1070, Vienna, Austria. helmut.schuetz@bebac.at.
Abstract:
In order to help companies qualify and validate the software used to evaluate bioequivalence trials in a replicate design intended for average bioequivalence with expanding limits, this work aims to define datasets with known results. This paper releases 30 reference datasets into the public domain along with proposed consensus results. A proposal is made for results that should be used as validation targets. The datasets were evaluated by seven different software packages according to methods proposed by the European Medicines Agency. For the estimation of CVwR and Method A, all software packages produced results that are in agreement across all datasets. Due to different approximations of the degrees of freedom, slight differences were observed in two software packages for Method B in highly incomplete datasets. All software packages were suitable for the estimation of CVwR and Method A. For Method B, different methods for approximating the denominator degrees of freedom could lead to slight differences, which eventually could lead to contrary decisions in very rare borderline cases.
Related Concept Videos
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence Data: Statistical Interpretation
Bioequivalence studies: Biowaivers
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence of Drugs: Drugs with Multiple Indications

